Seelos Therapeutics, Inc.SEC Filings
|
|
All SEC filings by Seelos Therapeutics, Inc. (SEELQ) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| NT 10-Q | Notice of late quarterly filing | Nov 22, 2024 | ||
| ARS | Annual report to shareholders | Aug 20, 2024 | ||
| 10-Q | Quarterly report | View Diff | Aug 14, 2024 | |
| 10-Q | Quarterly report | View Diff | May 14, 2024 | |
| 10-K/A | Annual report | View Diff | Apr 29, 2024 | |
| 10-K | Annual report | View Diff | Mar 6, 2024 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2023 | |
| 10-Q | Quarterly report | View Diff | Aug 11, 2023 | |
| 10-Q | Quarterly report | View Diff | May 12, 2023 | |
| ARS | Annual report to shareholders | Apr 12, 2023 |
Events
| 8-K | Bankruptcy or Receivership | Nov 22, 2024 | ||
| 8-K | Seelos Announces Second Postponement of Its Annual Meeting of Stockholders | Oct 24, 2024 | ||
| 8-K | Seelos Therapeutics Announces Notice of Delisting From Nasdaq and Transfer of Listing to Over-The-Counter Market | Oct 15, 2024 | ||
| 8-K | Other Events | Oct 7, 2024 | ||
| 8-K | Seelos Announces Postponement of Its Annual Meeting of Stockholders | Sep 26, 2024 | ||
| 8-K | Seelos Therapeutics Announces 1-For-16 Reverse Stock Split | Sep 25, 2024 | ||
| 8-K | Other Events | Sep 24, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | Sep 3, 2024 | ||
| 8-K | Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 | Aug 8, 2024 | ||
| 8-K | Other Events | Jul 26, 2024 |
Registrations and Prospectuses
| 25-NSE | Exchange delisting | Apr 4, 2025 | ||
| S-1 | IPO registration | View Diff | Sep 25, 2024 | |
| S-3 | Shelf registration | View Diff | Aug 16, 2024 | |
| D | $1.15 Mm in Options / Securities to Be Acquired, 3 Investors | Jul 30, 2024 | ||
| 424B3 | Prospectus supplement | Jun 25, 2024 | ||
| S-1 | IPO registration | View Diff | Jun 14, 2024 | |
| D | $2.04 Mm in Options / Securities to Be Acquired, 2 Investors | May 31, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | May 20, 2024 | ||
| 424B3 | Prospectus supplement | Mar 15, 2024 | ||
| S-8 | Registration of securities for employees | Mar 6, 2024 |
Proxies
| DEFA14A | Additional proxy soliciting materials | Oct 24, 2024 | ||
| DEFA14A | Additional proxy soliciting materials | Sep 26, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Aug 20, 2024 | |
| PRE 14A | Preliminary proxy | View Diff | Aug 9, 2024 | |
| DEFA14A | Additional proxy soliciting materials | Jan 2, 2024 | ||
| DEFA14A | Additional proxy soliciting materials | Dec 22, 2023 | ||
| DEFA14A | Additional proxy soliciting materials | Dec 22, 2023 | ||
| DEFA14A | Additional proxy soliciting materials | Dec 20, 2023 | ||
| DEFA14A | Additional proxy soliciting materials | Dec 20, 2023 | ||
| DEF 14A | Definitive proxy | View Diff | Dec 15, 2023 |
Other
| SEC STAFF ACTION | SEC staff action: Order | Sep 29, 2025 | ||
| EFFECT | Notice of effectiveness | Aug 26, 2024 | ||
| UPLOAD | Letter from SEC | Aug 22, 2024 | ||
| CORRESP | Correspondence with SEC | Aug 22, 2024 | ||
| EFFECT | Notice of effectiveness | Jun 26, 2024 | ||
| CORRESP | Correspondence with SEC | Jun 21, 2024 | ||
| UPLOAD | Letter from SEC | Jun 20, 2024 | ||
| EFFECT | Notice of effectiveness | Mar 18, 2024 | ||
| CORRESP | Correspondence with SEC | Mar 12, 2024 | ||
| CORRESP | Correspondence with SEC | Mar 6, 2024 |
Ownership
| SC 13G/A | Seelos Therapeutics, Inc. | Feb 14, 2025 | ||
| SC 13G | Seelos Therapeutics, Inc. | Feb 14, 2025 | ||
| SC 13G/A | Seelos Therapeutics, Inc. | Dec 4, 2024 | ||
| SC 13G | Seelos Therapeutics, Inc. | Nov 25, 2024 | ||
| SC 13G/A | Seelos Therapeutics, Inc. | Nov 14, 2024 | ||
| SC 13G | Seelos Therapeutics, Inc. | Nov 5, 2024 | ||
| 4 | Michael Joseph Golembiewski | Mar 1, 2024 | ||
| SC 13G | Seelos Therapeutics, Inc. | Feb 6, 2024 | ||
| 4 | Raj Mehra | Jan 17, 2024 | ||
| 4 | Michael Joseph Golembiewski | Jan 17, 2024 |